Louisiana and Gilead Sciences are working on a deal that would change how the state pays for expensive hepatitis C drugs, with the goal of eliminating the disease in that state.
Louisiana and Gilead Sciences are working on a deal that would change how the state pays for expensive hepatitis C drugs, with the goal of eliminating the disease in that state.